Dr. Nirvana A. Manning, MD
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 41
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
AR license E-5070
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- University of Arkansas Medical Sciences Little Rock, AR
Medical groups
- University of Arkansas for Medical Sciences (1,175 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 41
- Services billed
- 370
- Patients’ average age
- 62
| Service | Times | Patients |
|---|---|---|
| Screening 3d breast mammography | 42 | 40 |
| Screening mammography | 42 | 40 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 7 payments worth $5,571 in total to this clinician.
| Organon LLC | $5,555 |
|---|---|
| Sanara Medtech Inc. | $15.11 |
| Speaking at a medical education program | $5,555 |
|---|---|
| Food and Beverage | $15.11 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Organon LLC Sep 4, 2025 | Speaking at a medical education program NEXPLANON · ETONOGESTREL | $2,197 |
| Organon LLC Oct 16, 2025 | Speaking at a medical education program NEXPLANON · ETONOGESTREL | $1,521 |
| Organon LLC Dec 11, 2025 | Speaking at a medical education program NEXPLANON · ETONOGESTREL | $1,521 |
| Organon LLC Sep 4, 2025 | Speaking at a medical education program NEXPLANON · ETONOGESTREL | $253 |
| Organon LLC Oct 20, 2025 | Speaking at a medical education program NEXPLANON · ETONOGESTREL | $35.00 |
| Organon LLC Dec 18, 2025 | Speaking at a medical education program NEXPLANON · ETONOGESTREL | $28.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $17,300 in research payments for these studies, mostly to the institutions running them.
- CC-200086-Ostro Pilot Study
Philips North America LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.